Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone

M. Zarandi, J. E. Horvath, G. Halmos, J. Pinski, A. Nagy, K. Groot, Z. Rekasi, Andrew V Schally

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

In the search for antagonists of human growth hormone-releasing hormone (hGHRH) with high activity, 22 analogs were synthesized by solid-phase methods, purified, and tested biologically. Within the N-terminal sequence of 28 or 29 amino acids of hGHRH, all the analogs contained D-Arg2, Phe(4- Cl)6 (para-chlorophenylalanine), Abu15 (α-aminobutyric acid), and Nle27 and most of them had Agm29 (agmatine) substituents. All the peptides, except one, were acylated at the N terminus with different hydrophobic acids- e.g., isobutyric acid (Ibu) or 1-naphthylacetic acid (Nac) in order to study the effect of N-terminal acylation on the antagonistic activity. In the superfused rat pituitary cell system, all the analogs inhibited more powerfully the GHRH-induced growth hormone (GH) release than the standard GHRH antagonist [Ac-Tyr1,D-Arg2]hGHRH-(1-29)NH2. Antagonists [Ibu0,D- Arg2,Phe(4-Cl)6, Abu15,Nle27]hGHRH-(1-28)Agm (MZ-4-71), [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-28)Agm (MZ-4-243), [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2(MZ-4-169), [Nac0-His1,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]-hGHRH-(1-29)NH2 (MZ-4-181), and [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27,Asp28]hGHRH-(1-28)Agm (MZ-4-209) inhibited GH release at 3 x 10-9 M. Among these peptides, MZ-4-243, MZ-4- 169, and MZ-4-181 were also long acting in vitro. Antagonist MZ-4-243 inhibited GH release 100 times more powerfully than the standard antagonist and was the most potent in vitro among GHRH antagonists synthesized. Analogs with high inhibitory effects in vitro were also found to have high affinities to rat pituitary GHRH receptors. In experiments in vivo, antagonists [Ibu0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]-hGHRH-(1-28)Agm (MZ-4-71), [Nac0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2 (MZ-4-169), and [Nac0-His1,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2 (MZ-4-181) induced a significantly greater inhibition of GH release than the standard antagonist. In view of their high antagonistic activity and prolonged duration of action, some of these antagonists of GHRH may find clinical applications, including treatment of certain endocrine disorders and insulin- like growth factor I-dependent tumors.

Original languageEnglish
Pages (from-to)12298-12302
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume91
Issue number25
DOIs
StatePublished - Dec 6 1994
Externally publishedYes

Fingerprint

Growth Hormone-Releasing Hormone
Human Growth Hormone
Growth Hormone
Agmatine
Fenclonine
Aminobutyrates
Acylation
Insulin-Like Growth Factor I

Keywords

  • inhibitory growth hormone-releasing hormone analogs
  • structure-activity relationships

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. / Zarandi, M.; Horvath, J. E.; Halmos, G.; Pinski, J.; Nagy, A.; Groot, K.; Rekasi, Z.; Schally, Andrew V.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 91, No. 25, 06.12.1994, p. 12298-12302.

Research output: Contribution to journalArticle

Zarandi, M. ; Horvath, J. E. ; Halmos, G. ; Pinski, J. ; Nagy, A. ; Groot, K. ; Rekasi, Z. ; Schally, Andrew V. / Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. In: Proceedings of the National Academy of Sciences of the United States of America. 1994 ; Vol. 91, No. 25. pp. 12298-12302.
@article{03f2c5074df14859a11144f1b50490ad,
title = "Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone",
abstract = "In the search for antagonists of human growth hormone-releasing hormone (hGHRH) with high activity, 22 analogs were synthesized by solid-phase methods, purified, and tested biologically. Within the N-terminal sequence of 28 or 29 amino acids of hGHRH, all the analogs contained D-Arg2, Phe(4- Cl)6 (para-chlorophenylalanine), Abu15 (α-aminobutyric acid), and Nle27 and most of them had Agm29 (agmatine) substituents. All the peptides, except one, were acylated at the N terminus with different hydrophobic acids- e.g., isobutyric acid (Ibu) or 1-naphthylacetic acid (Nac) in order to study the effect of N-terminal acylation on the antagonistic activity. In the superfused rat pituitary cell system, all the analogs inhibited more powerfully the GHRH-induced growth hormone (GH) release than the standard GHRH antagonist [Ac-Tyr1,D-Arg2]hGHRH-(1-29)NH2. Antagonists [Ibu0,D- Arg2,Phe(4-Cl)6, Abu15,Nle27]hGHRH-(1-28)Agm (MZ-4-71), [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-28)Agm (MZ-4-243), [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2(MZ-4-169), [Nac0-His1,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]-hGHRH-(1-29)NH2 (MZ-4-181), and [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27,Asp28]hGHRH-(1-28)Agm (MZ-4-209) inhibited GH release at 3 x 10-9 M. Among these peptides, MZ-4-243, MZ-4- 169, and MZ-4-181 were also long acting in vitro. Antagonist MZ-4-243 inhibited GH release 100 times more powerfully than the standard antagonist and was the most potent in vitro among GHRH antagonists synthesized. Analogs with high inhibitory effects in vitro were also found to have high affinities to rat pituitary GHRH receptors. In experiments in vivo, antagonists [Ibu0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]-hGHRH-(1-28)Agm (MZ-4-71), [Nac0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2 (MZ-4-169), and [Nac0-His1,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2 (MZ-4-181) induced a significantly greater inhibition of GH release than the standard antagonist. In view of their high antagonistic activity and prolonged duration of action, some of these antagonists of GHRH may find clinical applications, including treatment of certain endocrine disorders and insulin- like growth factor I-dependent tumors.",
keywords = "inhibitory growth hormone-releasing hormone analogs, structure-activity relationships",
author = "M. Zarandi and Horvath, {J. E.} and G. Halmos and J. Pinski and A. Nagy and K. Groot and Z. Rekasi and Schally, {Andrew V}",
year = "1994",
month = "12",
day = "6",
doi = "10.1073/pnas.91.25.12298",
language = "English",
volume = "91",
pages = "12298--12302",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "25",

}

TY - JOUR

T1 - Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone

AU - Zarandi, M.

AU - Horvath, J. E.

AU - Halmos, G.

AU - Pinski, J.

AU - Nagy, A.

AU - Groot, K.

AU - Rekasi, Z.

AU - Schally, Andrew V

PY - 1994/12/6

Y1 - 1994/12/6

N2 - In the search for antagonists of human growth hormone-releasing hormone (hGHRH) with high activity, 22 analogs were synthesized by solid-phase methods, purified, and tested biologically. Within the N-terminal sequence of 28 or 29 amino acids of hGHRH, all the analogs contained D-Arg2, Phe(4- Cl)6 (para-chlorophenylalanine), Abu15 (α-aminobutyric acid), and Nle27 and most of them had Agm29 (agmatine) substituents. All the peptides, except one, were acylated at the N terminus with different hydrophobic acids- e.g., isobutyric acid (Ibu) or 1-naphthylacetic acid (Nac) in order to study the effect of N-terminal acylation on the antagonistic activity. In the superfused rat pituitary cell system, all the analogs inhibited more powerfully the GHRH-induced growth hormone (GH) release than the standard GHRH antagonist [Ac-Tyr1,D-Arg2]hGHRH-(1-29)NH2. Antagonists [Ibu0,D- Arg2,Phe(4-Cl)6, Abu15,Nle27]hGHRH-(1-28)Agm (MZ-4-71), [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-28)Agm (MZ-4-243), [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2(MZ-4-169), [Nac0-His1,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]-hGHRH-(1-29)NH2 (MZ-4-181), and [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27,Asp28]hGHRH-(1-28)Agm (MZ-4-209) inhibited GH release at 3 x 10-9 M. Among these peptides, MZ-4-243, MZ-4- 169, and MZ-4-181 were also long acting in vitro. Antagonist MZ-4-243 inhibited GH release 100 times more powerfully than the standard antagonist and was the most potent in vitro among GHRH antagonists synthesized. Analogs with high inhibitory effects in vitro were also found to have high affinities to rat pituitary GHRH receptors. In experiments in vivo, antagonists [Ibu0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]-hGHRH-(1-28)Agm (MZ-4-71), [Nac0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2 (MZ-4-169), and [Nac0-His1,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2 (MZ-4-181) induced a significantly greater inhibition of GH release than the standard antagonist. In view of their high antagonistic activity and prolonged duration of action, some of these antagonists of GHRH may find clinical applications, including treatment of certain endocrine disorders and insulin- like growth factor I-dependent tumors.

AB - In the search for antagonists of human growth hormone-releasing hormone (hGHRH) with high activity, 22 analogs were synthesized by solid-phase methods, purified, and tested biologically. Within the N-terminal sequence of 28 or 29 amino acids of hGHRH, all the analogs contained D-Arg2, Phe(4- Cl)6 (para-chlorophenylalanine), Abu15 (α-aminobutyric acid), and Nle27 and most of them had Agm29 (agmatine) substituents. All the peptides, except one, were acylated at the N terminus with different hydrophobic acids- e.g., isobutyric acid (Ibu) or 1-naphthylacetic acid (Nac) in order to study the effect of N-terminal acylation on the antagonistic activity. In the superfused rat pituitary cell system, all the analogs inhibited more powerfully the GHRH-induced growth hormone (GH) release than the standard GHRH antagonist [Ac-Tyr1,D-Arg2]hGHRH-(1-29)NH2. Antagonists [Ibu0,D- Arg2,Phe(4-Cl)6, Abu15,Nle27]hGHRH-(1-28)Agm (MZ-4-71), [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-28)Agm (MZ-4-243), [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2(MZ-4-169), [Nac0-His1,D- Arg2,Phe(4-Cl)6,Abu15,Nle27]-hGHRH-(1-29)NH2 (MZ-4-181), and [Nac0,D- Arg2,Phe(4-Cl)6,Abu15,Nle27,Asp28]hGHRH-(1-28)Agm (MZ-4-209) inhibited GH release at 3 x 10-9 M. Among these peptides, MZ-4-243, MZ-4- 169, and MZ-4-181 were also long acting in vitro. Antagonist MZ-4-243 inhibited GH release 100 times more powerfully than the standard antagonist and was the most potent in vitro among GHRH antagonists synthesized. Analogs with high inhibitory effects in vitro were also found to have high affinities to rat pituitary GHRH receptors. In experiments in vivo, antagonists [Ibu0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]-hGHRH-(1-28)Agm (MZ-4-71), [Nac0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2 (MZ-4-169), and [Nac0-His1,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]hGHRH-(1-29)NH2 (MZ-4-181) induced a significantly greater inhibition of GH release than the standard antagonist. In view of their high antagonistic activity and prolonged duration of action, some of these antagonists of GHRH may find clinical applications, including treatment of certain endocrine disorders and insulin- like growth factor I-dependent tumors.

KW - inhibitory growth hormone-releasing hormone analogs

KW - structure-activity relationships

UR - http://www.scopus.com/inward/record.url?scp=0027973393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027973393&partnerID=8YFLogxK

U2 - 10.1073/pnas.91.25.12298

DO - 10.1073/pnas.91.25.12298

M3 - Article

C2 - 7991622

AN - SCOPUS:0027973393

VL - 91

SP - 12298

EP - 12302

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 25

ER -